Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzetti, Alessandro, Bacchiarri, Francesca, Sammartano, Vincenzo, Defina, Marzia, Sicuranza, Anna, Mecacci, Bianca, Zappone, Elisabetta, Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://www.ncbi.nlm.nih.gov/pubmed/33415072
http://dx.doi.org/10.3389/fonc.2020.570187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://www.ncbi.nlm.nih.gov/pubmed/33415072
http://dx.doi.org/10.3389/fonc.2020.570187

Ejemplares similares